WO2006071804A2 - Vecteurs, cellules hotes a base d'anticorps anti-il-12 et procedes de production de ceux-ci et utilisations de ceux-ci - Google Patents

Vecteurs, cellules hotes a base d'anticorps anti-il-12 et procedes de production de ceux-ci et utilisations de ceux-ci Download PDF

Info

Publication number
WO2006071804A2
WO2006071804A2 PCT/US2005/046885 US2005046885W WO2006071804A2 WO 2006071804 A2 WO2006071804 A2 WO 2006071804A2 US 2005046885 W US2005046885 W US 2005046885W WO 2006071804 A2 WO2006071804 A2 WO 2006071804A2
Authority
WO
WIPO (PCT)
Prior art keywords
vector
antibody
sequences
expression
promoter
Prior art date
Application number
PCT/US2005/046885
Other languages
English (en)
Other versions
WO2006071804A3 (fr
Inventor
Jin Lu
Thomas Nesspor
Bernard Scallon
Linda Snyder
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Priority to SI200531791T priority Critical patent/SI1839120T1/sl
Priority to ES05855447.8T priority patent/ES2440777T3/es
Priority to US11/722,281 priority patent/US7736650B2/en
Priority to EP05855447.8A priority patent/EP1839120B1/fr
Priority to DK05855447.8T priority patent/DK1839120T3/da
Priority to PL05855447T priority patent/PL1839120T3/pl
Publication of WO2006071804A2 publication Critical patent/WO2006071804A2/fr
Publication of WO2006071804A3 publication Critical patent/WO2006071804A3/fr
Priority to US12/759,154 priority patent/US8361474B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Definitions

  • the present invention relates to vectors and plasmids directing expression of an antibody, host cells, and methods of making and using thereof, including specific vector enhancer and promoter sequences and their interaction with host cell transcription factors.
  • BACKGROUND Antibody molecules consist of a combination of two heavy (H) chain and two light (L) chain polypeptides.
  • Each heavy and light chain comprises a constant region containing the CL, CHl, hinge region, CH2, and CH3 regions, and a variable region containing the hypervariable regions (complement determining regions (CDRs)); the CDRs control the antibody's antigen-binding characteristics.
  • the two heavy chains are joined to each other and the light chains in a Y-shaped structure via disulfide bridges such that the variable regions of the light chains (V.sub.L) and heavy chains (V.sub.H) are located next to each other.
  • a mammalian expression vector will contain (1) regulatory elements, usually in the form of viral promoter or enhancer sequences and characterized by a broad host and tissue range; (2) a "polylinker" sequence, facilitating the insertion of a DNA fragment within the plasmid vector; and (3) the sequences responsible for intron splicing and polyadenylation of mRNA transcripts. This contiguous region of the promoter-polylinker- polyadenylation site is commonly referred to as the transcription unit.
  • the vector will likely also contain (4) a selectable marker gene(s) (e.g., the .beta.-lactamase gene), often conferring resistance to an antibiotic (such as ampicillin), allowing selection of initial positive transformants in E. coli; and (5) sequences facilitating the replication of the vector in both bacterial and mammalian hosts.
  • a selectable marker gene(s) e.g., the .beta.-lactamase gene
  • an antibiotic such as ampicillin
  • antibody genes are assembled from gene segments that may be widely separated in the germ line.
  • heavy chain genes are formed by recombination of three genomic segments encoding the variable (V), diversity (D) and joining (J)/constant (C) regions of the antibody.
  • Functional light chain genes are formed by joining two gene segments; one encodes the V region and the other encodes the J/C region.
  • Both the heavy chain and .kappa, light chain loci contain many V gene segments (estimates vary between 100s and 1000s) estimated to span well over 1000 kb.
  • the .lambda, locus is, by contrast, much smaller and has been shown to span approximately 300 kb on chromosome 16 in the mouse.
  • CDM8 An example of a mammalian expression vector is CDM8.
  • the transcription unit of CDM8 is composed of a chimeric promoter (the human cytomegalovirus AD 169 constitutive promoter fused to the T7 RNA polymerase promoter), a polylinker region and the SV40 small tumor (t) antigen splice and early region polyadenylation signals derived from pSV2.
  • the human cytomegalovirus (HCMV) promoter is expressed in a variety of mammalian cell types, while the T7 bacteriophage DNA- dependent RNA polymerase promoter can drive in vitro cell-free transcription/translation of cloned inserts.
  • This particular promoter fusion allows initial experiments to be conducted within the confines of the host mammalian cell type, while further analysis and utilization of the cloned insert may potentially be carried out in an in vitro "cell-free" transcription/translation system.
  • the constitutively expressed HCMV promoter has also been utilized in other mammalian expression vectors besides CDM8. Origins of replication in CDM8 include (1) .pi. VX (allowing e.g., replication in E.
  • coli (2) SV40 origin (e.g., allowing replication in a variety of COS cell types) (3) polyoma origin (e.g., allowing replication in polyoma virus transformed mouse fibroblasts) and (4) the bacteriophage M13 origin (e.g., allowing generation of single-stranded template for DNA sequence analysis and/or oligonucleotide site-directed mutagenesis).
  • SV40 origin e.g., allowing replication in a variety of COS cell types
  • polyoma origin e.g., allowing replication in polyoma virus transformed mouse fibroblasts
  • bacteriophage M13 origin e.g., allowing generation of single-stranded template for DNA sequence analysis and/or oligonucleotide site-directed mutagenesis.
  • CDM8 carries the supF gene for selection in E. coli.
  • a CDM8-based plasmid construction is transformed into a specialized E. coli strain containing an episome carrying genes encoding resistance to the antibiotics, arnpicillin and tetracyline.
  • both genes contain chain termination ("nonsense" codon) point mutations inactivating the resistance phenotype.
  • the supF gene product, a nonsense suppressor tRNA restores the resistant phenotype for each antibiotic. Therefore, selection is based on growth of the specialized episomal- carrying E. coli strain on media containing ampicillin and tetracycline.
  • the CDM8 vector is compatible with COS cell lines as well as cell lines transformed with the polyoma virus.
  • COS cell lines are African green monkey CVl cells transformed with an origin- defective SV40 mutant virus.
  • the COS cells produce the large T antigen, which is required in trans to promote replication of SV40 or plasmid constructions, such as CDM8, which contain the respective cis-actmg sequences initiating viral replication Therefore, COS cells transfected with a CDM8-based construction will support replication of the plasmid, resulting m increased plasmid copy number and a transient overexpression of the gene of interest.
  • CDM8 The major use of CDM8 is cDNA expression cloning and overproduction of specific proteins in a mammalian m vitro expression system.
  • Expression clonmg takes on va ⁇ ous forms depending on the mode of detection utilized to identify the cDNA of interest; however, the initial step consists of isolating mRNA and synthesizing double-stranded deoxyribonucleic acid copies of the mRNA population (cDNAs).
  • cDNAs double-stranded deoxyribonucleic acid copies of the mRNA population
  • the CDM8 vector contains two BstXI restriction sites, making it amenable to the "adaptor" linker procedure of hgatmg cDNAs to the vector, i.e., the use of DNA fragments blunt ended at one end (and therefore compatible for ligation with the blunt ended cDNA) but containing a non-palmdromic overhang (sticky end) on the other end (m this instance, compatible for ligation with BstXI digested vector DNA, but not with other cDNAs).
  • pCMX mammalian expression vector
  • This vector contains: (1) the immediate early promoter of HCMV, (2) an SV40 RNA splice/polyadenylation sequence, (3) an SV40 origin of replication, (4) apBR322 origin of replication, and (5) a selectable marker conferring resistance to an antibiotic, such as the .beta -lactamase gene conferring resistance to the antibiotic ampicillm.
  • the pCMX vector can also be used for the transient expression of a cloned DNA sequence in transfected COS cells.
  • Control of transcription of both rearranged heavy and .kappa, light chain genes depends both on the activity of a tissue specific promoter upstream of the V region and a tissue specific enhancer located in the J-C mtron. These elements act synergistically. Also, a second B-cell specific enhancer has been identified in the .kappa light chain locus. This further enhancer is located 9 kb downstream ofC.sub..kappa.
  • One such mammalian host system used to produce antibodies is a mouse myeloma host cell that has been transfected with cloned DNA encoding the desired antibody.
  • Such "recombinant monoclonal antibodies” are often distinct from hybridoma-de ⁇ ved monoclonal antibodies for which the DNA has not been cloned and for which the cells producing the monoclonal antibody are derived by immortalizing a natural monoclonal antibody-producing cell isolated from an animal.
  • the heavy and light chain immunoglobulin (Ig) genes being expressed m hyb ⁇ doma cells are under the control of the natural endogenous promoter that had always been linked to the particular variable region sequence being expressed as opposed to the promoter contained m the recombinant vector
  • the monoclonal antibody sequence to be cloned must be hgated into an approp ⁇ ate vector after restriction enzyme treatment of the vector This task can be difficult and imprecise as the process of incorporating the antibody nucleotide sequence(s) into an expression vector or plasmid is complex.
  • recombinant DNA methods can be used to replace the natural endogenous promoter for an Ig gene with any promoter of choice.
  • a primary reason for changing a promoter is to realize higher monoclonal antibody production levels.
  • Promoter sequences in conjunction with downstream enhancer sequences, are responsible for driving transcription (i.e., RNA synthesis) of the heavy and light chain genes in the transfected cells by binding to specialized nuclear proteins called transcription factors. It has become apparent that there are fewer sites for transcription factor binding in an Ig promoter than there are in an Ig enhancer; however, the fact that there is sequence variability among promoters but only a single copy of an enhancer sequence makes it highly likely that there is functional variability among Ig promoters.
  • One promoter may be "strong,” i.e., efficient at binding a favorable combination of transcription factors that leads to high levels of monoclonal antibody RNA synthesis, whereas another promoter may be "weak,” due to having a different DNA sequence.
  • Ig promoters are only functional in lymphoid-type host cells, such as T cells and B cells (and myeloma cells), due to their requirement for Ig gene-specific transcription factors (for example, Oct-2 and OBF-I) not expressed in other cell types.
  • lymphoid cell-specific transcription factors may be expressed only at particular stages of cellular differentiation such that optimal expression may depend on matching the differentiation state of the host cell line with the appropriate sequence motifs in the Ig gene promoters.
  • the host cell specificity of Ig promoters may be seen as a minor disadvantage for expression of the monoclonal antibody in a non-lymphoid host cell, the large assortment of HC and LC promoters affords a chance to identify and perhaps further optimize strong promoters that can be incorporated into lymphoid cell-specific vectors.
  • Ig vectors with strong promoters are highly desirable for expressing any monoclonal antibody of interest.
  • vectors with unique DNA cloning sites downstream of strong promoters would have an added convenience.
  • the present invention relates to recombinant expression vectors and plasmids comprising restriction sites for cloning of various antibodies
  • the invention provides expression control sequences m the vector, such as enhancer and promoter sequences, that can be customized related to the antibody gene to be cloned and transcribed and the host cell type to be used, m order to drive transcription efficiently.
  • the present invention also comp ⁇ ses isolated host cells, e g., mammalian and non-mammalian cells, containing such a vector or plasmid
  • the invention further provides methods for producing an antibody by cultu ⁇ ng, in a suitable medium, a host cell containing a recombinant expression vector of the invention such that the antibody is produced.
  • the invention comp ⁇ ses a method for identifying, modulating, and/or determining the interaction between host cell transcription factors and promoter and enhancer sequences of an expression vector. This interaction drives the transcription process
  • the transcription factors and promoter and enhancer sequences can be customized to improve their affinity for or binding to each other, which can increase the yield and efficiency of the transcription process
  • the present invention further provides any invention desc ⁇ bed herein
  • Fig. IA is a schematic depiction of the vector map for plasmid pl560
  • Fig. IB is a schematic depiction of the vector map for plasmid pi 558
  • an "activity,” a biological activity, and a functional activity of a polypeptide refer to an activity exerted by a protein or polypeptide in response to its specific interaction with another protein or molecule as determined in vivo, m situ, or in vitro, according to standard techniques. Such activities can be a direct activity, such as an association with or an enzymatic activity on a second protein, or an indirect activity, such as a cellular process mediated by interaction of the protein with a second protein or a se ⁇ es of interactions as in intracellular signalling or the coagulation cascade.
  • an “antibody” includes any polypeptide or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to, at least one complementarity determmng region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain va ⁇ able region, a heavy chain or light chain constant region, a framework region, or any portion, fragment or variant thereof.
  • CDR complementarity determmng region
  • antibody is further intended to encompass antibodies, digestion fragments, specified portions and va ⁇ ants thereof, including antibody mimetics or comprising portions of antibodies that mimic the structure and/or function of an anitbody or specified fragment or portion thereof, including single chain antibodies and fragments thereof.
  • antibody fragments include, but are not limited to, Fab (e.g., by papain digestion), Fab' (e.g., by pepsin digestion and partial reduction) and F(ab')2 (e.g., by pepsin digestion), facb (e.g., by plasmin digestion), pFc' (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction and reaggregation), Fv or scFv (e.g., by molecular biology techniques) fragments, are encompassed by the invention (see, e.g., Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY (1994-2001); Colligan et al., Current Protocols in Polypeptide Science, John Wiley & Sons, NY, NY, (1997-2001)).
  • Fab e.g., by papain digestion
  • Chimeric or “fusion” molecules are nucleic acids or polypeptides that are created by combining one or more of polynucleotides (or their parts) with additional nucleic acid sequence(s). Such combined sequences may be introduced into an appropriate vector and expressed to give rise to a chimeric or fusion polypeptide.
  • “Complement of or “complementary to” a nucleic acid sequence of the invention refers to a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a first polynucleotide.
  • “Fragment” is a variant polypeptide having an amino acid sequence that is entirely the same as part but not all of any amino acid sequence of a polypeptide or a variant polynucleotide having a nucleic acid sequence that is entirely the same as part but not all of any nucleic acid sequence of any polynucleotide.
  • Fragments can include, e.g., truncation polypeptides having a portion of an amino acid sequence, or of variants thereof, such as a continuous series of residues that includes a heterologous amino- and/or carboxy-terminal amino acid sequence. Degradation forms of the polypeptides produced by or in a host cell are also included.
  • fragments are characterized by structural or functional attributes, such as fragments that comprise alpha-helix or alpha-helix forming regions, beta-sheet or beta-sheet forming regions, turn or turn-forming regions, coil or coil-forming regions, hydrophilic regions, hydrophobic regions, alpha-amphipathic regions, beta-amphipathic regions, flexible regions, surface-forming regions, substrate binding regions, extracellular regions, and high antigenic index regions.
  • fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from a full-length amino acid sequence, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the full-length amino acid sequence. Fragments also include isolated polynucleotides having similar sizes and characteristics. "Identity,” as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as determined by the match between strings of such sequences.
  • identity and similarity can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing:Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York,
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al.,
  • BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBINLM NIH Bethesda, Md. 20894: Altschul, S., et al., J. MoI. Biol. 215:403-410 (1990).
  • the well-known Smith Waterman algorithm may also be used to determine identity.
  • Preferred parameters for polypeptide sequence comparison include the following:
  • the aforementioned parameters are the default parameters for peptide sequence comparisons (along with no penalty for end gaps).
  • Preferred parameters for polynucleotide comparison include the following:
  • Gap Penalty 50 Gap Length Penalty: 3
  • a polynucleotide sequence may be identical to a sequence, that is be
  • nucleotide alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein the alterations may occur at the 5 ' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides m the reference sequence or m one or more contiguous groups within the reference sequence.
  • the number of nucleotide alterations is determined by multiplying the total number of nucleotides in the sequence by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from the total number of nucleotides in the sequence, or.
  • n.sub.n ltorsim x.sub.n -(x.sub.n.y), wherein n.sub.n is the number of nucleotide alterations, x.sub n is the total number of nucleotides in the sequence, and y is, for instance, 0 70 for 70%, 0 80 for 80%, 0.85 for 85%, 0.90 for 90%, 0 95 for 95%, etc., and wherein any non-mteger product of x.s ⁇ b.n and y is rounded down to the nearest integer prior to subtracting from x sub.n.
  • a polypeptide sequence may be identical to a reference sequence, that is be 100% identical, or it may include up to a certain integer number of ammo acid alterations as compared to the reference sequence such that the percentage identity is less than 100%
  • Such alterations are selected from the group consisting of at least one ammo acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein the alterations may occur at the ammo- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids in the reference sequence or m one or more contiguous groups within the reference sequence
  • the number of ammo acid alterations for a given % identity is determined by multiplying the total number of ammo acids in the sequence by the numerical
  • Nucleic acids are polymers of nucleotides, wherein a nucleotide comprises a base linked to a sugar which sugars are in turn linked one to another by an interceding at least bivalent molecule, such as phosphoric acid.
  • the sugar is either 2'-deoxyribose (DNA) or ⁇ bose (RNA).
  • Unnatural poly- or oligonucleotides contain modified bases, sugars, or linking molecules, but are generally understood to mimic the complementary nature of the naturally occurring nucleic acids after which they are designed.
  • An example of an unnatural oligonucleotide is an antisense molecule composition that has a phosphorothiorate backbone.
  • oligonucleotide generally refers to nucleic acids having less than 30 nucleotides.
  • a "polypeptide” is a polymer of amino acid residues joined by peptide bonds, and a peptide generally refers to amino acid polymers of 12 or less residues. Peptide bonds can be produced naturally as directed by the nucleic acid template or synthetically by methods well known in the art.
  • a "protein” is a macromolecule comprising one or more polypeptide chains. A protein may further comprise substituent groups attached to the side groups of the amino acids not involved in formation of the peptide bonds. Typically, proteins formed by eukaryotic cell expression also contain carbohydrates. Proteins are defined herein in terms of their amino acid sequence or backbone and substituents are not specified, whether known or not.
  • receptor denotes a molecule having biological activity resulting from interaction with a specific ligand or binding partner.
  • Cell membrane bound receptors are characterized by an extracellular ligand-binding domain, one or more membrane spanning or transmembrane domains, and an intracellular effector domain that is typically involved in signal transduction.
  • Ligand binding to cell membrane receptors causes changes in the extracellular domain that are communicated across the cell membrane, direct or indirect interaction with one or more intracellular proteins, and alters cellular properties, such as enzyme activity, cell shape, or gene expression profile.
  • Receptors may also be untethered to the cell surface and may be cytosolic, nuclear, or released from the cell altogether. Non-cell associated receptors are termed soluble receptors.
  • the invention provides vectors, preferably, expression vectors, containing a nucleic acid encoding a specific polypeptide, for example, the anti-IL-12 antibody, or may be used to obtain plasmids containing various antibody HC or LC genes or portions thereof.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector wherein additional DNA segments can be ligated into the viral genome.
  • vectors are capable of autonomous replication in a host cell mto which they are introduced (e g , bacte ⁇ al vectors having a bacterial origin of replication and episomal mammalian vectors)
  • Other vectors e g., non-episomal mammalian vectors
  • expression vectors are capable of directing the expression of genes to which they are operably linked
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors)
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e g , replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions
  • the recombinant expression vectors of the invention comprise a nucleic acid m a form suitable for expression of the nucleic acid m a form suitable for expression of the nucleic acid m a form suitable for expression of the nucleic acid m a form suitable for expression of
  • the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed
  • "operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) m a manner which allows for expression of the nucleotide sequence (e.g., m an in vitro transcription/translation system or in a host cell when the vector is introduced mto the host cell).
  • the regulatory sequence is optimized based on the host cell charactensitics, i.e., transcription factors.
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only m certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
  • the expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion and chime ⁇ c proteins or peptides, encoded by nucleic acids as described herein.
  • the recombinant expression vectors of the invention can be designed for expression of a polypeptide in prokaryotic (e.g., E col ⁇ ) or eukaryotic cells (e.g., insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further m Goeddel, supra.
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of ammo acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
  • Such fusion vectors typically serve three purposes: (1) to increase expression of recombinant protein; (2) to increase the solubility of the recombinant protein; and (3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, NJ.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S-transferase
  • maltose E binding protein or protein A, respectively
  • tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his- gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field et al., MoI. Cell.
  • tag polypeptides include the Flag-peptide (Hopp et al., Bio Technology, 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al., Science, 255:192-194 (1992)); an .alpha.-tubulin epitope peptide (Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393- 6397 (1990)).
  • a preferred tag is the FLAG tag.
  • Suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1 Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89).
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.
  • Target gene expression from the pET 1 Id vector relies on transcription from a T7 gnlO- lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ⁇ prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
  • One strategy to maximize recombinant protein expression in E. coli is to express the protein in host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzyrnology 185, Academic Press, San Diego, Calif. (1990) 119-128).
  • Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
  • the expression vector is a yeast expression vector.
  • yeast expression vectors for expression in yeast S. cerevisiae include pYepSecl (Baldari et al. (1987) EMBOJ. 6:229- 234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and pPicZ (Invitrogen Corp, San Diego, Calif.).
  • the expression vector is a baculovirus expression vector.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) MoI. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
  • a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector.
  • mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBOJ. 6:187-195).
  • the expression vector's control functions are often provided by viral regulatory elements.
  • commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., supra.
  • the recombinant mammalian expression vector is capable of directing expression of the nucleic acid, preferentially in a particular cell type, such as lymphoma cells (e.g., mouse myeloma cells).
  • tissue-specific regulatory elements are used to express the nucleic acid. Tissue-specific regulatory elements are known in the art.
  • suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) ⁇ v. Immunol. 43:235-275), in particular, promoters of T cell receptors (Winoto and Baltimore (1989) EMBOJ.
  • promoters are also encompassed, for example, by the murine hox promoters (Kessel and Grass (1990) Science 249:374-379) and the ⁇ -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
  • the invention further provides a recombinant expression vector comprising a DNA molecule cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to the mRNA encoding a polypeptide. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types. For instance, viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific, or cell type specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • a recombinant plasmid plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced.
  • the terms "host cell” and "recombinant host cell” are used interchangeably herein.
  • a host cell can be any prokaryotic (e.g., E. col ⁇ ) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells) .
  • eukaryotic cell e.g., insect cells, yeast or mammalian cells
  • suitable mammalian host cell lines capable of expressing intact glycosylated polypeptides have been developed in the art, and include the COS-I (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-IO), CHO (e.g., ATCC CRL 1610) and BSC-I (e.g., ATCC CRL-26) cell lines, Cos-7 cells, CHO cells, hep G2 cells,
  • Expression vectors for these cells can include one or more of the following expression control sequences, a promoter, an enhancer, and/or processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences (See, e.g., Ausubel et al., supra; Sambrook, et al., supra).
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE- dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.
  • a gene that encodes a selectable marker is generally introduced into the host cells along with the gene of interest.
  • Preferred selectable markers include those that confer resistance to drugs, such as, chloramphenicol, tetracyclines, gentamycm, kanamycin, ampicillm, G418, hygromycin, methotrexate, etc Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e g , cells that have incorporated the selectable marker gene will survive, while the other cells die)
  • drugs such as, chloramphenicol, tetracyclines, gentamycm, kanamycin, ampicillm, G418, hygromycin, methotrexate, etc
  • a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide (e g , a protein or antibody)
  • the invention further provides methods for producing a polypeptide using the host cells of the invention
  • the method comprises cultu ⁇ ng the host cell of the invention (into which a recombinant expression vector encoding a polypeptide has been introduced) in a suitable medium such that the polypeptide is produced
  • the method further comp ⁇ ses isolating the polypeptide from the medium or the host cell.
  • the host cells of the invention can also be used to produce nonhuman transgenic animals.
  • a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which at least one sequence encoding a polypeptide has been introduced
  • Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide have been introduced into their genome or homologous recombinant animals in which endogenous sequences encoding a polypeptide have been altered
  • Such animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity.
  • transgenic animal is a non-human animal, preferably, a mammal, more preferably, a rodent, such as a rat or mouse, in which one or more of the cells of the animal includes a transgene.
  • rodent such as a rat or mouse
  • transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc.
  • a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal
  • a "homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
  • a transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • Intronic sequences and polyadenylation signals can also be included m the transgene to increase the efficiency of expression of the transgene.
  • a tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide to particular cells.
  • transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.
  • a vector which contains at least a portion of a gene encoding a polypeptide into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene.
  • the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).
  • the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein).
  • the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell.
  • the additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene.
  • flanking DNA both at the 5' and 3' ends
  • flanking DNA both at the 5' and 3' ends
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al. (1992) Cell 69:915).
  • the selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (ERL, Oxford, 1987) pp. 113-152).
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
  • Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in
  • transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene.
  • One example of such a system is the cre/loxP recombinase system of bacteriophage Pl .
  • cre/loxP recombinase system of bacteriophage Pl .
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al (1991) Science 251 1351-1355) If a cre/loxP recombmase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombmase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombmase.
  • Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385 810-813 and PCT Publication Nos WO 97/07668 and WO 97/07669.
  • the present invention further includes, but is not limited to, methods of using nucleic acids and polypeptides encoded thereby to make antibodies and anti-idiotype antibodies, including diagnostic and therapeutic compositions, methods and devices
  • Such antibodies optionally further affect a specific hgand, such as but not limited to, where such antibody modulates, decreases, increases, antagonizes, agonizes, mitigates, aleviates, blocks, inhibits, abrogates and/or interferes with at least one protein activity or binding, or with receptor activity or binding, in vitro, m situ and/or in vivo
  • a suitable antibody, specified portion or va ⁇ ant can bind at least one protein, or specified portions, variants or domains thereof
  • a suitable antibody, specified portion, or va ⁇ ant can also optionally affect at least one of protein activity or function, such as but not limited to, RNA, DNA or polypeptide synthesis, protein release, receptor signaling, membrane cleavage, protein activity, protein production and/or synthesis.
  • an "antibody,” and the like include any polypeptide or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule, such as but not limited to, at least one complementarity determinng region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain va ⁇ able region, a heavy chain or light chain constant region, a framework region, or any portion, fragment or va ⁇ ant thereof, or at least one portion of a receptor or binding polypeptide, which can be incorporated into an antibody.
  • CDR complementarity determinng region
  • Antibodies can include one or more of at least one CDR, at least one variable region, at least one constant region, at least one heavy chain (e g., gl, g2, g3, g4, m, al, a2, d, e), at least one light chain (e.g , kappa and lambda), or any portion or fragment thereof, and can further comp ⁇ se interchain and intracham disulfide bonds, hinge regions, glycosylation sites that can be separated by a hinge region, as well as heavy chains and light chains Light chains typically have a molecular weight of about 25Kd and heavy chains typically range from 50K-77Kd Light chains can exist in two distinct forms or lsotypes, kappa (k) and lambda (1), which can combine with any of the heavy chain types.
  • heavy chain e.g., gl, g2, g3, g4, m, al, a2, d, e
  • at least one light chain e.g , k
  • All light chains have at least one va ⁇ able region and at least one constant region
  • the IgG antibody is considered a typical antibody structure and has two intrachain disulfide bonds in the light chain (one in variable region and one in the constant region), with four in the heavy chain, and such bond encompassing a peptide loop of about 60-70 amino acids comprising a "domain" of about 110 amino acids in the chain.
  • IgG antibodies can be characterized into four classes, IgGl, IgG2, IgG3 and IgG4. Each immunoglobulin class has a different set of functions. The following table summarizes the Physicochemical properties of each of the immunoglobulin classes and subclasses.
  • an antibody is produced by any of these methods, its amino acid and corresponding gene sequences can be identified and, optionally, modified (e.g., optimized, humanized, etc.) such that the antibody can then be produced recombinantly.
  • a specified polypeptide, or a fragment thereof can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation.
  • the full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens.
  • the antigenic peptide comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of a protein's sequence and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.
  • An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject, such as a rabbit, goat, mouse, or other mammal or vertebrate.
  • a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate.
  • An appropriate immunogenic preparation can contain, for example, recombinantly expressed or chemically synthesized polypeptide.
  • the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.
  • Antibody-producing cells can be obtained from the peripheral blood or, preferably, the spleen or lymph nodes of humans or other suitable animals that have been immunized with the immunogen of interest. Any other suitable host cell can also be used for expressing heterologous or endogenous nucleic acid encoding an antibody, specified fragment or variant thereof.
  • the fused cells (hybridomas) or recombinant cells can be isolated using selective culture conditions or other suitable known methods, and cloned by limiting dilution or cell sorting, or other known methods. Cells that produce antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA).
  • a hybridoma is produced by fusing a suitable immortal cell line (e.g., a myeloma cell line, such as, but not limited to, Sp2/0, Sp2/0-AG14, NSO, NSl, NS2, AE-I, L.5, >243, P3X63Ag8.653, Sp2 SA3, Sp2 MAI, Sp2 SSl, Sp2 SA5, U937, MLA 144, ACT IV, MOLT4, DA-I, JURKAT, WEHI, K-562, COS, RAJI, NIH 3T3, HL-60, MLA 144, NAMALWA, NEURO 2A, or the like), or heteromyelomas, fusion products thereof, or any cell or fusion cell derived therefrom, or any other suitable cell line as known in the art (see, e.g., www.atcc.org, www.lifetech.com, and the like), with antibody producing cells, such as, but not limited to, isolated or
  • Suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or polypeptide library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, or the like, display library, e g , as available from Cambridge antibody Technologies, Cambridgeshire, UK, MorphoSys, Martmsreid/Planegg, DE, Biovation, Aberdeen, Scotland, UK, Biolnvent, Lund, Sweden, Dyax Corp , Enzon, Affymax/Biosite, Xoma, Berkeley, CA, Ixsys.
  • AME Applied Molecular Evolution
  • transgenic animals e g., SCID mice, Nguyen et al., Microbiol. Immunol. 41:901-907 (1997); Sandhu et al , C ⁇ t. Rev. Biotechnol. 16 95-118 (1996), Eren et al., Immunol 93-154-161 (1998), each entirely incorporated by reference as well as related patents and applications
  • Such techniques include, but are not limited to, ⁇ bosome display (Hanes et al., Proc. Natl.
  • a humanized or engineered antibody has one or more ammo acid residues from a source that is non-human, e.g., but not limited to, mouse, rat, rabbit, non-human p ⁇ mate or other mammal. These human ammo acid residues are often referred to as "import" residues, which are typically taken from an "import" variable, constant or other domain of a known human sequence.
  • Such imported sequences can be used to reduce immunogenicity or reduce, enhance or O modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art.
  • part or all of the non-human or human CDR sequences are maintained while the non-human sequences of the variable and constant regions are replaced with human or other amino acids.
  • Antibodies can also optionally be humanized with retention of high affinity for the antigen and other favorable biological properties.
  • humanized 5 antibodies can be optionally prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Humanization or engineering of antibodies of the present invention can be performed using any known method, such as but not limited to, those described in, Winter (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), Sims et al, J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. MoI. Biol. 196:901 (1987), Carter et al, Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), U.S.
  • Antibodies can also be optionally generated by immunization of a transgenic animal (e.g., mouse, rat, hamster, non-human primate, and the like) capable of producing a repertoire of human antibodies, as described herein and/or as known in the art.
  • a transgenic animal e.g., mouse, rat, hamster, non-human primate, and the like
  • Cells that produce an antibody can be isolated from such animals and immortalized using suitable methods, such as the methods described herein.
  • Transgenic mice that can produce a repertoire of human antibodies that bind to human antigens can be produced by known methods (e.g., but not limited to, U.S. Pat. Nos: 5,770,428, 5,569,825, 5,545,806, 5,625,126, 5,625,825, 5,633,425, 5,661,016 and 5,789,650 issued to Lonberg et al; Jakobovits et al. WO 98/50433, Jakobovits et al. WO 98/24893, Lonberg et al. WO 98/24884, Lonberg et al. WO 97/13852, Lonberg et al.
  • mice comprise at least one transgene comprising
  • Antibodies can also be prepared in milk by administering at least one antibody encoding nucleic acid to transgenic animals or mammals, such as goats, cows, horses, sheep, and the like, that produce antibodies in their milk. Such animals can be provided using known methods. See, e.g., but not limited to, U.S. Patent Nos.
  • Antibodies can additionally be prepared using at least one antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (e.g., but not limited to, tobacco and maize) that produce such antibodies, specified portions or variants in the plant parts or in cells cultured therefrom.
  • the antibodies can bind antigens with a wide range of affinities (K D ).
  • at least one human monoclonal antibody of the present invention can optionally bind its antigen with high affinity.
  • a human monoclonal antibody can bind human antigen with a K 0 equal to or less than about ICT 7 M, such as but not limited to, 0.1-9.9 (or any range or value therein) X 10 "7 , 10 "8 , 10 "9 JO '10 , 10 “l l » 10 "12 , 10 "13 or any range or value therein.
  • the affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method.
  • any suitable method See, for example, Berzofsky, et al , "Antibody-Antigen Interactions," In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, NY (1984); Kuby, Jams Immunology, W. H. Freeman and Company: New York, NY (1992); and methods desc ⁇ bed herein).
  • the measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g., salt concentration, pH).
  • measurements of affinity and other antigen- bmding parameters are preferably made with standardized solutions of antibody and antigen, and a standardized buffer, such as the buffer desc ⁇ bed herein.
  • An antibody directed against a polypeptide can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or lmmunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide.
  • the antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance.
  • detectable substances include va ⁇ ous enzymes, prosthetic groups, fluorescent materials, luminescent materials, biolummescent mate ⁇ als, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamme, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent mate ⁇ al includes luminol;
  • biolummescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 1, 131 1, 35 S or 3 H.
  • Transfected cell lines C379B and C381B were observed to be robust producers of a human monoclonal antibody to the cytokine IL- 12 (anti-IL-12 antibody or IL- 12 mAb) encoded by fully human Ig HC and LC genes
  • the invention provides the complete DNA sequences of the HC and LC expression plasmids used to create the C379B and C381B cell lines and containing the anti-IL-12 antibody gene.
  • the vectors and plasmids have been engineered to enable convenient one-step insertion of various antibody variable region genes.
  • the vector is used in a one-step process to replace the anti-IL-12 variable region sequence with a variable region sequence encoding another monoclonal antibody of interest, for example, an antibody for a human interleukin, a growth factor, etc. Additionally, the vectors and plasmids allow for the replacement of antibody constant regions.
  • the maps of two expression plasmids according to the invention, pl560 and pl558, are depicted schematically in Figs. IA and IB. Their sequences are disclosed in SEQ ID NOS: 11 and 12.
  • the HC plasmid specifically described herein, pi 560 encodes constant regions of the human IgGl isotype.
  • the LC plasmid specifically described herein, pl558, encodes a constant region of the human kappa isotype.
  • the complete DNA sequence for each of the two plasmids is around 20 kb in length and their selected features, including, without limitation, the positioning of the various expression control polynucleotide sequences, are listed in Table 1.
  • the antibody genes in these two plasmids are presented in reverse/complement orientation in order for the pSV2gpt vector backbones to be presented in their conventional orientation, as depicted in Figures IA and IB. Consequently, nucleotide position numbers corresponding to the carboxyl- terminal end of the antibody coding sequence (CH3 coding sequence) are lower and nucleotide position numbers corresponding to the amino-terminal end of the antibody coding sequence (V region cloning site) are higher, hi addition, all antibody coding sequences correspond to the 'minus strand' as presented in the sequences shown here. This orientation is reasonable for the description of transcription factor binding sites since such binding sites may map to either the 'plus strand' or 'minus strand.'
  • Vectors of the present invention can be used to express the constant region sequences from human IgGl, IgG2, IgG3, IgG4, IgD, IgE, or IgM, mouse IgGl, IgG2a, IgG2b, or IgG3, or rat IgGl, IgG2a, IgG2b, or IgG2c.
  • vectors of the present invention can be used to express the ⁇ CH1 versions of the above listed constant region sequences.
  • Any antibody, immunoglobulin derived protein, fusion protein, other protein, or portion thereof can be subsituted for the V region coding sequence in the vectors/plasmids of the present invention, e.g., extracellular domain of a TNF receptor.
  • a fusion protein that includes the CHl domain some form of LC would be required for secretion out of the cell.
  • the pi 560 HC expression plasmid as shown schematically herein contains the HC promoter and intron enhancer; however, the promoter and enhancer type can be varied.
  • the pi 560 HC expression plasmid contains a unique constant region coding sequence. It is an allotypic variant that encodes an Arg residue at position 214 (Glm(l,3) allotype) instead of the Lys residue (GIm(1, 17 allotype).
  • mouse-specific transcription factor models were built with different parameters for a matrix search (Goessling et al., 2001).
  • a mouse lymphocyte transcription factor specific model was also constructed for a matrix search.
  • patch searches for different subsequence lengths (6 bps and above) were performed.
  • mice TFs 21 potential binding sites for mouse TFs were identified (Table 2). Most of these TFs were B lymphocyte-specific. Some of the TFs may be activated during different stages of B cell development. Their activations are also dependent on the presence of other binding sites and the interaction of other factors.
  • the TRANSFAC database accession codes for these mouse TFs are: T00032 for ApI; TO 1575 for STATx; TOOlIl for c-Ets-1; TO 1852 for HMGJY; T00479 for Lyf-1; T00278 for YYl; T00613 for NF-Y; T00989 for CREB; T00402 for ERF; T02057 for IPFl; T00422 for LRF-I ; T01432 for cMaf; T00814 for TFE3-S; T00017 for C/EBPBeta; TOIl 14 for C/EBPdelta; T01864 for
  • POU2F2/Oct-2 POU2F2/Oct-2; T00644 for POU2Fla/Oct-l; T00651 for POU5Fl/Oct-3; T00702 for PU.l; T00169 for c-Rel; and TOl 159 for TFIID.
  • TFs were found to be located 500 bp upstream of the transcription initiation site. These are mouse POU2F2/Oct-2, POU2Fla/Oct-l, POU5Fl/Oct-3, PU.l, c-Rel, and TFIID.
  • the following auxiliary TFs or TFs in association with enhancer functions were identified: Ap 1 ; STATx; c-Ets- 1 ; HMG_rY; Lyf-1; YYl and TFHD.
  • Binding site ID is the TF binding site identification assigned by TRANSFAC database
  • Core score indicates core binding score calculated by TRANSFAC for the five most conserved consecutive nucleotides used in a matrix Score is from 0 to 1, with 1 being the best score For patch search the core score is 0
  • - Match/patch score indicates the similarity of a subsequence to a matrix of TRANSFAC Score is from 0 to 1 with 1 being the best match If the score is 100, it was a Patch search - Source/Search method indicates whether immuno cell specific matrix model, high quality matrix model, and/or patch search method used
  • the LC gene promoter region was analyzed by the same methods, which yielded a list of 20 potential mouse transcription factors and their binding sites (shown m Table 3).
  • the TRANSFAC database accession codes for these TFs are T02057 for IPFl, T01786 for E12, T00169 for c-Rel, T00549 for NF-AT, T01675 for NKx2-5, T01575 for STATx, T01852 for HMGIY, TOOlIl for c-Ets- 1, T00702 for PU 1, T00278 for YYl, T00032 for ApI, T01429 for Sox-5, T00017 for C/EBPBeta, T00814 for TF3-S, T01554 for Mitf, T01159 forTFIED, T00613 for NF-Y, T01114 for C/EBPdelta, TO 1864 for POU2F2/Oct-2, and T00644 for POU2
  • POU2Fla/Oct-l, Sox-5, E12, Statx, NF-Y, TFE3-S, Mitf, C/EBPbeta, TFIID, and POU2F were found to be located in the 500 bps upstream of the transcription start site.
  • Light cham auxiliary TFs were ApI, STATx, c-ETS-1, HMGIY, YYl, and TFIK).
  • the unique HC and LC promoters described here have been shown to be capable of driving high levels of gene expression, as in the case of the C379B and C381B transfected cell lines.
  • the identification of sequence motifs that can determine transcriptional levels provides information to enhance gene transcription by customizing promoter and enhancer sequences and using host cells that express the best combination of transcription factors for these promoters. This could include using a host cell that has been modified to overexpress transcription factors that can enhance expression and/or a host cell that has been modified to underexpress transcription factors that may impede expression, among others.
  • host cells can be co-transfected with a gene encoding OBF-I transcription factor to obtain higher OBF-I levels, or using anti-sense, interfering RNA (e.g., siRNA or shRNA), or gene knockout approaches to reduce expression of TFs that may negatively regulate Ig gene transcription, e,g. NF- ⁇ NR.
  • a gene encoding OBF-I transcription factor to obtain higher OBF-I levels
  • anti-sense e.g., siRNA or shRNA
  • gene knockout approaches to reduce expression of TFs that may negatively regulate Ig gene transcription, e,g. NF- ⁇ NR.
  • the present invention also comprises methods of identifying the interaction between the sequences of promoter and enhancer regions and transcription factors in vectors/plasmids and cellular hosts, moderating the interaction by altering the sequences to effect transciption, translation, and gene expression levels, and determining the modifications and adjusting in order to control the levels.
  • the sequence alteration may be by mutations to the sequences in the regions or by complete replacement of the regions compatible with the cell line used.
  • EXAMPLE 1 Cloning of human anti-human interleukin-12 antibody genes and preparation of high-producing cell lines Summary
  • the C340A hyb ⁇ doma cell lme that secretes the human anti-human IL-12 r ⁇ Ab produces less than 0.4 ⁇ g/ml of spent cell culture This level of production was insufficient to generate the large amounts of material needed for future studies.
  • the IL-12 mAb heavy and light chain genes were cloned and introduced mto P3X63Ag8 653 (653) or SP2/0-Agl4 (SP2/0) mouse myeloma cells
  • the IL-12 mAb heavy and light chain genes were cloned from a bacte ⁇ ophage library prepared from C340A hyb ⁇ doma genomic DNA and transferred into plasmid vectors
  • the resulting heavy and light chain expression plasmids were then sequenced and the sequences compared to known germlme sequences
  • These plasmids were introduced into mouse myeloma cells and transfected clones were screened for human IgG expression by ELISA to identify the highest producers.
  • T ⁇ sol was obtained from Gibco BRL, Grand Island, NY. Proteinase K was from Sigma Chemical, St Lois, MO. Rest ⁇ ction en2ymes were purchased from New England Biolabs, Beverly, MA. The Lambda EMBL3/Gigapack m Gold Cloning Kit was from Stratagene, La Jolla, CA.
  • RNAse and the Random Prime Labeling Kit were from Boehrmger Mannheim, Germany.
  • DNAse was from Pharmacia, Uppsala, Sweden
  • ⁇ - 32 P-dCTP was purchased from DuPont NEN, Boston, MA.
  • Human BL- 12 was purchased from RDI Immunochemicals, Flanders, NJ.
  • Custom oligonucleotides were purchased from Biosource International, Camar ⁇ llo, CA. The names, sequence identification numbers, and sequences of the oligonucleotides used in this work are as follows: Name SEO ID Sequence
  • genomic DNA was isolated from 5 x 10 7 cells by digestion with 0.1 mg/ml proteinase K in a buffer containing 100 mM NaCl, 10 mM Tris-Cl (pH 8.0), 25 mM EDTA (pH 8.0) and 0.5% SDS, and subsequent phenol/chloroform extraction and ethanol precipitation. Two hundred ⁇ gs of C340 genomic DNA were then digested with 8 units/ml Sau3A restriction enzyme and aliquots were taken every 5 minutes.
  • the purified genomic DNA fragments were ligated into the Lambda EMBL3 bacteriophage vector and packaged into bacteriophage particles using the Lambda EMBL3/Gigapack III Gold Cloning Kit according to the manufacturer's protocol.
  • the final genomic library consisted of approximately 1 million clones.
  • Probes for the heavy and light chains were prepared using genomic DNA fragments that contained either human IgGl heavy chain constant region sequences (2.8 kb EcoRl/Hindlll fragment from p747) or human kappa light chain constant region sequences (2.4 kb Ncol/Xba fragment from p95). Both probes were labeled with ⁇ - 32 P-dCTP using a Random Primed DNA Labeling Kit.
  • Nitrocellulose membranes were prehybridized for one hour in hybridization buffer (50% formamide, 5X SSC, 3.75 mM Tris pH 7.8, IX Denhardts Solution, 25 ⁇ g/ml sheared DNA and 5% dextran sulfate).
  • Probes with a CPM of approximately I X lO 8 were denatured at 100°C then added to the hybridization buffer and allowed to hybridize at 42 0 C overnight. Filters were washed twice in 2X SSC, 0.1% SDS for 10 minutes at RT, then twice in 0.2X SSC, 0.1% SDS at 65 0 C with shaking. Filters were dried and exposed to x-ray film.
  • DNA was purified from the positive bacteriophage clones using a liquid culture method. Two hundred ⁇ l of Y1090r- bacterial culture was combined with 100 ⁇ l of bacteriophage in IX lambda dilution buffer and the mixture was incubated at
  • RNAse and 20 ⁇ g of DNAse were added and the samples incubated at 37°C for 30 minutes.
  • 20 ml of a solution containing 20% PEG and 2.5 M NaCl was then added and the samples incubated on ice for 1.5 hours.
  • the bacteriophage particles were pelleted and then washed once with IX lambda dilution buffer. The pellet was then resuspended in a solution of 0.2% SDS and 20 mM EDTA and incubated at 68EC for 15 minutes. The DNA was extracted from the bacteriophage particles using phenol and chloroform, and then the DNA was precipitated with isopropanol and washed with 70% ethanol. The purified DNA was resuspended in
  • PCR was used to determine which, if any, of the clones contained human variable regions in addition to the constant region known to be present based on homology to the radiolabeled probes. Because the sequence of the variable regions at the 5' ends was unknown, primers were pooled and used to prime the sequencing reactions. For the HC reactions, a mix of four primers, 5'-10, 5'-46, 5'- 63, and 5'-73, representing each of the possible sequences was used. At the 3' end, primers huJH4 and huJH6 which are homologus to either the JH4 or JH6 regions were used.
  • LC For the LC, at the 5' end, a mixture of two consensus primers 5'VKl and 5'VK2 was used At the 3' end, p ⁇ mers huJK3 or huJK5 homologous to the JK3 or JK5 regions were used Standard 100 ⁇ l PCR reactions were performed using 0 5 nanograms of phage DNA as template P ⁇ mers were annealed at 48°C and 25 cycles of PCR were performed Reactions were fractionated on an agarose gel for visualization To transfer the cloned inserts from the bacte ⁇ ophage vector to a plasmid that contains the gpt selectable marker gene, bacte ⁇ ophage DNA from clones containing both the va ⁇ able and constant regions were digested with Sail.
  • the resulting fragments were purified and cloned between the Xhol and Sail sites of plasmid pl351. Because there was an internal Sail site in the heavy chain vanable region coding sequence, two Sail fragments that were 13 kb and 4 kb in size had to be transferred into the pl351 expression vector sequentially. First the 13 kb Sail fragment was cloned into the Xhol and Sail sites of pl351 and the resulting plasmid designated pl557. Subsequently, the 4 kb fragment was transferred into pl557 and the resulting final expression plasmid was termed pl560. The 15 kb light chain Sail insert was able to be transferred in one step and the final expression plasmid was designated p 1558 Cell Transfections, Screening for High Producers and Expression of the Cloned Genes
  • Heavy chain plasmid pi 560 was hnea ⁇ zed by digestion with Pvul rest ⁇ ction enzyme and light chain plasmid pl558 was linearized using Sail rest ⁇ ction enzyme 653 and SP2/0 cells were separately transfected with the premixed linea ⁇ zed plasmids by electroporation and cells cultured and transfectants selected using mycophenolic acid as described Cell supernatants from mycophenolic acid-resistant colonies were assayed approximately two weeks later for human IgG.
  • the subclones selected for final analyses were the 653 transfectant C379B and the SP2/0 transfectants C381B Maximal production levels for C379B and C381B were 135 ⁇ g/ml and 150 ⁇ g/ml, respectively. Peak cell densities for C379B and C381B were 1 X 10 6 cells/ml and 1.45 X 10 6 cells/ml, respectively.
  • the cloned insert containing the IL-12 mAb light chain coding sequences is approximately 15 kb m length.
  • the start codon is located 4310 base pairs from the 5' end of the insert
  • the light chain constant region is the Km(3) allotype, the same as cA2 and 7E3.
  • the cloned insert containing the IL-12 mAb heavy chain coding sequences is approximately 16 kb in length.
  • the start codon is located 4802 bp from the 5' end of the insert
  • the IgG allotype is Glm(f), defined by the argmme (arg) at position 214. This is different than cA2 which has a lysine (lys) at position 214 and is therefore of the Glm(z) allotype.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des vecteurs d'expression et des plasmides d'anticorps pouvant renfermer diverses parties de gènes d'anticorps aux fins de transcription de l'ADN d'anticorps et d'expression de l'anticorps dans une cellule hôte appropriée. Les vecteurs d'expression et plasmides comprennent des sites d'enzymes de restriction facilitant la ligature de l'ADN de codage d'anticorps en vecteurs. Ceux-ci comprennent des séquences d'amplificateurs et de promoteurs pouvant être variées de manière à interagir avec des facteurs de transcription dans la cellule hôte et commander ainsi la transcription de l'ADN de codage d'anticorps. L'invention concerne également un kit renfermant ces vecteurs et plasmides.
PCT/US2005/046885 2004-12-21 2005-12-21 Vecteurs, cellules hotes a base d'anticorps anti-il-12 et procedes de production de ceux-ci et utilisations de ceux-ci WO2006071804A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SI200531791T SI1839120T1 (sl) 2004-12-21 2005-12-21 Vektorji na osnovi protitelesa anti-il-12, gostiteljske celice in postopki proizvodnje ter uporabe
ES05855447.8T ES2440777T3 (es) 2004-12-21 2005-12-21 Vectores basados en anticuerpo anti-il-12, células huéspedes y métodos de producción y usos
US11/722,281 US7736650B2 (en) 2004-12-21 2005-12-21 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
EP05855447.8A EP1839120B1 (fr) 2004-12-21 2005-12-21 Vecteurs, cellules hotes a base d'anticorps anti-il-12 et procedes de production de ceux-ci et utilisations de ceux-ci
DK05855447.8T DK1839120T3 (da) 2004-12-21 2005-12-21 Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser
PL05855447T PL1839120T3 (pl) 2004-12-21 2005-12-21 Wektory oparte na przeciwciałach anty-IL-12, komórki gospodarza oraz metody wytwarzania i zastosowania
US12/759,154 US8361474B2 (en) 2004-12-21 2010-04-13 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63793604P 2004-12-21 2004-12-21
US60/637,936 2004-12-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/722,281 A-371-Of-International US7736650B2 (en) 2004-12-21 2005-12-21 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
US12/759,154 Division US8361474B2 (en) 2004-12-21 2010-04-13 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses

Publications (2)

Publication Number Publication Date
WO2006071804A2 true WO2006071804A2 (fr) 2006-07-06
WO2006071804A3 WO2006071804A3 (fr) 2007-07-26

Family

ID=36615455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046885 WO2006071804A2 (fr) 2004-12-21 2005-12-21 Vecteurs, cellules hotes a base d'anticorps anti-il-12 et procedes de production de ceux-ci et utilisations de ceux-ci

Country Status (8)

Country Link
US (2) US7736650B2 (fr)
EP (1) EP1839120B1 (fr)
DK (1) DK1839120T3 (fr)
ES (1) ES2440777T3 (fr)
PL (1) PL1839120T3 (fr)
PT (1) PT1839120E (fr)
SI (1) SI1839120T1 (fr)
WO (1) WO2006071804A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736650B2 (en) * 2004-12-21 2010-06-15 Centocor, Inc. Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
EP2214708A2 (fr) * 2007-10-26 2010-08-11 Centocor Ortho Biotech Inc. Vecteurs, cellules hôtes, procédés de production et utilisations
WO2014102100A1 (fr) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Intron hétérologue dans un domaine d'immunoglobuline
WO2014102101A1 (fr) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Séquences de nouveaux introns
WO2014102103A3 (fr) * 2012-12-31 2014-08-28 Boehringer Ingelheim International Gmbh Intron hétérologue dans un peptide signal
US9493803B2 (en) 2012-12-31 2016-11-15 Boehringer Ingelheim International Gmbh Artificial introns

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2165162C (fr) 1993-06-14 2000-05-23 Hermann Bujard Regulation etroite de l'expression de genes dans les cellules d'eucaryotes, grace a des promoteurs sensibles a la tetracycline
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2003031569A2 (fr) * 2001-10-10 2003-04-17 Centocor, Inc. Vaccins a base d'acides nucleiques utilisant des acides nucleiques codant pour un antigene tumoral et un acide nucleique codant pour un adjuvant cytokine
US20040156832A1 (en) * 2002-09-30 2004-08-12 Centec Limited Immunoglobulin compositions and methods
SI1839120T1 (sl) * 2004-12-21 2013-12-31 Janssen Biotech, Inc. Vektorji na osnovi protitelesa anti-il-12, gostiteljske celice in postopki proizvodnje ter uporabe
JP2008523842A (ja) * 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOGAN: "Manipulating the Mouse Embryo", COLD SPRING HARBOR LABORATORY PRESS
JONES ET AL., NATURE, vol. 321, 1986, pages 522
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323
See also references of EP1839120A4

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361474B2 (en) 2004-12-21 2013-01-29 Centocor, Inc. Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
US7736650B2 (en) * 2004-12-21 2010-06-15 Centocor, Inc. Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
US9206248B2 (en) 2007-10-26 2015-12-08 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
EP2214708A4 (fr) * 2007-10-26 2011-01-12 Centocor Ortho Biotech Inc Vecteurs, cellules hôtes, procédés de production et utilisations
US8663980B2 (en) 2007-10-26 2014-03-04 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
US8980626B2 (en) 2007-10-26 2015-03-17 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
EP2214708A2 (fr) * 2007-10-26 2010-08-11 Centocor Ortho Biotech Inc. Vecteurs, cellules hôtes, procédés de production et utilisations
WO2014102100A1 (fr) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Intron hétérologue dans un domaine d'immunoglobuline
WO2014102101A1 (fr) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Séquences de nouveaux introns
WO2014102103A3 (fr) * 2012-12-31 2014-08-28 Boehringer Ingelheim International Gmbh Intron hétérologue dans un peptide signal
US9243053B2 (en) 2012-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Heterologous intron within an immunoglobulin domain
US9249201B2 (en) 2012-12-31 2016-02-02 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
US9493803B2 (en) 2012-12-31 2016-11-15 Boehringer Ingelheim International Gmbh Artificial introns
US9708636B2 (en) 2012-12-31 2017-07-18 Boehringer Ingelheim International Gmbh Artificial introns

Also Published As

Publication number Publication date
PL1839120T3 (pl) 2014-04-30
EP1839120A4 (fr) 2008-03-26
WO2006071804A3 (fr) 2007-07-26
US20100216234A1 (en) 2010-08-26
PT1839120E (pt) 2014-01-03
EP1839120A2 (fr) 2007-10-03
ES2440777T3 (es) 2014-01-30
US8361474B2 (en) 2013-01-29
US7736650B2 (en) 2010-06-15
US20080299133A1 (en) 2008-12-04
DK1839120T3 (da) 2013-11-11
EP1839120B1 (fr) 2013-10-23
SI1839120T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
AU2019203048B2 (en) Express humanization of antibodies
JP6101489B2 (ja) 親和性が低下した抗体およびそれを作製する方法
US6214613B1 (en) Expression screening vector
US8361474B2 (en) Anti-IL-12 antibody based vectors, host cells, and methods of production and uses
US9206248B2 (en) Vectors, host cells, and methods of production and uses
MX2015000885A (es) Identificacion mediada por trasposición de proteínas de unión o funcionales específicas.
JP2008531049A (ja) ヘテロ二量体タンパク質結合組成物
US20050260642A1 (en) CNGH0011 polynucleotides, polypeptides, antibodies, and compositions, and methods of production and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11722281

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005855447

Country of ref document: EP